EP1142865A1 — Novel 1,2-diphenyl-2-propen-1-one derivatives
Assigned to Santen Pharmaceutical Co Ltd · Expires 2001-10-10 · 25y expired
What this patent protects
The present invention provides compounds represented by the following formula [I] or salts thereof which lower intraocular pressure by causing morphological change in trabecular meshwork cells. In the formula, R 1 is H, lower alkyl, hydroxy, lower alkoxy or halogen, R 2 , R 3 a…
USPTO Abstract
The present invention provides compounds represented by the following formula [I] or salts thereof which lower intraocular pressure by causing morphological change in trabecular meshwork cells. In the formula, R 1 is H, lower alkyl, hydroxy, lower alkoxy or halogen, R 2 , R 3 and R 4 are H or lower alkyl, and ··· is a single bond or a double bond. When R 3 and/or R 4 is hydrogen, the amino can be protected by a protecting group.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.